Abstract

The objective: to establish the prevalence of the G894T polymorphism of the NOS3 gene among patients with primary arterial hypertension (AH) with overweight and its effect on the course of the disease.Material and methods. 58 patients with AH and body mass index (BMI) of <25 kg/m2 were examined: 22 (38%) men and 38 (62%) women; middle-aged: 53,6±8,7 years. 3 (5%) patients had impaired carbohydrate tolerance, 10 (17%) had type 2 diabetes. 48 patients with hypertension stage I, 5 – stage II and 5 – stage III.Results. The «wild» homozygous genotype GG was detected in 35 (60,3%) patients, the heterozygous genotype GT – in 20 (34.5%) and the «mutant» homozygous TT genotype – in 3 (5,2%) patients. Allele G has 94,8% of those surveyed, allele T – 39,7% of patients. The debut of hypertension on average in patients with the homozygous TT genotype at 38,7 years old, in patients with the GT genotype at 47,5 years old and in patients with the homozygous GG genotype at 43,6 years old. The presence of the T allele in patients with AH with overweight is associated with a significantly lower average level of mean daily systolic and diastolic blood pressure (122,6±22,1 mm Hg vs 132,3±16,5 mm Hg vs; р<0,05 and 76,5±8,1 mm Hg vs. 84,5±16,5 mm Hg vs; р<0,05).Conclusion. The majority (60,3%) of patients with AH and overweight had GG genotype of the G894T NOS3 polymorphism, 34,5% and 5,2% respectively had GT and TT genotypes, while among healthy individuals there were 28,9%, 67,5% and 3,6%. Patients with the GT genotype fell ill with AH 4,5 years earlier than patients with the GG genotype (5,7±4,2 years vs. 10,2±6,0 years; р<0,005). The presence of the T allele of this gene in patients receiving antihypertensive therapy is associated with better control of systolic and diastolic blood pressure than in patients of the comparison group (122,6±22,1 mm Hg vs., 132,3±16,5 mm Hg vs.; р<0,05 and 76,5±8,1 mm Hg vs, 84,5±16,5 mm Hg vs; р<0,05).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call